Needham raised the firm’s price target on Cellebrite (CLBT) to $28 from $21 and keeps a Buy rating on the shares. The firm remains positive on the company driving durable low to mid 20% ARR – annual recurring revenue growth, particularly as the Inseyets upgrade cycle becomes more apparent, the analyst tells investors in a research note. Needham adds that Cellebrite’s strong growth attributes are complemented by expanding EBITDA margins, with management guiding to 24%-25% in 2024, also noting that the investment in US Federal is still an under-appreciated aspect of the Cellebrite story.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLBT:
- Cellebrite price target raised to $24 from $22 at Deutsche Bank
- Cellebrite Strengthens Board with New Appointments for 2025 Growth
- Cellebrite appoints Capellas to board of directors, updates board positions
- Cellebrite price target raised to $24 from $22 at JPMorgan
- Cellebrite price target raised to $25 from $23 at TD Cowen